TITLE

Willing participant

PUB. DATE
July 1991
SOURCE
New Scientist;7/20/91, Vol. 131 Issue 1778, p2
SOURCE TYPE
Periodical
DOC. TYPE
Letter
ABSTRACT
Presents a letter to the editor of the journal 'New Scientist' commenting on reservations expressed by Ann Oakley in the column 'Talking Point' about trials at the Royal Marsden Hospital in London, England, to test the use of Tamoxifen for the prevention of breast cancer.
ACCESSION #
10556327

 

Related Articles

  • Breast cancer advocates take aim at industry polluters.  // HealthFacts;Nov95, Vol. 20 Issue 198, p3 

    Reports on Massachusetts-based Women's Community Cancer Project's drive against environmental pollution in an effort to prevent breast cancer. Launching of the National Cancer Industry Awareness Month in October 1995; Indifference towards the use of tamoxifen as an anti-cancer drug.

  • Tamoxifen guidelines for breast cancer prevention premature, researcher says.  // Formulary;Jun98, Vol. 33 Issue 6, p512 

    Reveals that the development of formal guidelines for the use of tamoxifen for breast cancer prevention is premature, according to Richard Clarfeld, clinical professor of surgery at the University of Washington. Results of long-term tamoxifen therapy in the Breast Cancer Prevention Trial; Use...

  • Cancer preventer. Brownlee, Shannon // U.S. News & World Report;04/20/98, Vol. 124 Issue 15, p63 

    Reports on the announcement regarding tamoxifen, a drug which reduces the chance of women developing breast cancer. Reasons why studies on the drug were ended a year early; Side effects and dangers in taking the drug.

  • Prevent breast cancer. Gregory, Deborah // Essence (Essence);Sep93, Vol. 24 Issue 5, p44 

    Discusses the Breast Cancer Prevention Trial aimed at examining the preventive capability of tamoxifen. Number of black women enrolled in breast-cancer studies; Tamoxifen's mechanism of action; Requirement for study participants; Contact information.

  • COMMENTARY. Chouinard, Edmond // Evidence Based Medicine;Jul2003, p110 

    The author comments on the effectiveness of tamoxifen as breast cancer chemoprevention in women in Canada.

  • Tamoxifen as a breast cancer preventive--many questions remain.  // HealthFacts;May98, Vol. 23 Issue 5, p1 

    Focuses on complications associated with the use of tamoxifen for the prevention of breast cancer in high-risk women. Pulmonary embolism; Criticism of the use of tamoxifen in the Breast Cancer Prevention Trial; Description of the drug.

  • Breast cancer prevention trail shows major benefits, some risk. Smigel, Kara // JNCI: Journal of the National Cancer Institute;05/06/98, Vol. 90 Issue 9, p647 

    Presents information on the finding from the Brest Cancer Prevention Trial in relation to use of tamoxifen. Effects of the drug; Comments made by Bernard Fisher, medical doctor, scientific director of the National Surgical Adjuvant Breast and Bowel Project; Results of the trial. INSET: Breast...

  • Tamoxifen for breast cancer prevention called one of the most cost-effective interventions in...  // Formulary;Apr2000, Vol. 35 Issue 4, p307 

    Reports on the use of tamoxifen for breast cancer prevention as the most cost-effective in high-risk women. Need for third-party taxpayers to consider tamoxifen for reimbursement just as they do for other cost-effective preventive drugs and procedures; Illustrative example.

  • Mobilizing the Mammobile. Cousino, Richard E. // Saturday Evening Post;Apr86, Vol. 258 Issue 3, p6 

    Presents a letter to the editor in response to the article "Prevent breast cancer deaths" in the March 1986 issue.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics